Search the Newsreel

Xenon plans Aug. 6 webcast for results and business update

Xenon Pharmaceuticals (Nasdaq: XENE) will report its Q2 2026 financial results and provide a business update on Thursday, August 6, 2026, after the U.S. markets close. A webcast and company presentation will follow at 4:30 p.m. ET. The company will likely discuss its lead …

Xenetic Biosciences Inc (XBIO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Xenetic Biosciences Inc (XBIO) as of July 30, 2026. The company currently holds a valuation score of 8.31, ranking 140 out of 384 in its industry, with a P/E ratio of -2.14. The article notes that relevant …

Xenetic Biosciences Inc (XBIO) Institutional Confidence

Xenetic Biosciences Inc (XBIO) currently holds an institutional shareholding score of 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 53.00% quarter-over-quarter, now standing at 4.97%. James Simons is identified as the …

Xenetic Biosciences Inc (XBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Xenetic Biosciences Inc (XBIO), highlighting its current risk score of 1.12, which ranks 326 out of 385 in the Biotechnology & Medical Research industry. It details the company's beta value of 2.12, indicating higher volatility compared to …

Xenetic Biosciences, Inc. Revenue Breakdown – MUN:3XB0

This article provides a revenue breakdown for Xenetic Biosciences, Inc. (MUN:3XB0), highlighting the United States as its primary revenue source. In the last year, the U.S. contributed €2.53 million, closely following €2.42 million from the previous year. The information is presented within the context …

Xenetic Biosciences Inc (XBIO) Financial Health: Profitability & Balance Sheet Analysis

Xenetic Biosciences Inc (XBIO) has a strong financial health score of 8.45, ranking 44th in the Biotechnology & Medical Research industry. The company reported a significant year-over-year revenue increase of 36.01% to $806.92K and a net profit increase of 49.47%. Despite its robust financial …

Xenetic Biosciences Inc (XBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for Xenetic Biosciences Inc (XBIO). It indicates that the company has not distributed any dividends in the past five years. However, it lists a 10-to-1 merger-related stock split event that occurred on May …

Xenon Pharmaceuticals Inc (XENE) Institutional Confidence

Xenon Pharmaceuticals Inc (XENE) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional ownership stands at 116.66%, a 21.96% increase quarter-over-quarter. Paul Tudor Jones is the largest institutional shareholder, holding 534.69K shares, which represents 0.51% …

Xenon Pharmaceuticals Inc (XENE) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Xenon Pharmaceuticals Inc (XENE) shareholder structure, listing major shareholders, their proportion of holdings, and a classification of shareholder types. It also includes institutional shareholding trends over several quarters and recent shareholder activity with changes in holdings for …

Xenetic Biosciences Inc (XBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown of Xenetic Biosciences Inc (XBIO), noting that relevant data regarding business segments, regional revenue, and profit contribution has not been disclosed by the company. It highlights the current stock price, market capitalization, and indicates a lack of detailed …

Xenon Pharmaceuticals Inc (XENE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Xenon Pharmaceuticals Inc (XENE) stock, focusing on its dividend and stock split history. It notes that the company has distributed a total of $0.00 in dividends over the past five years, indicating no payout history. The page also …

XBIO|Xenetic Biosciences Inc|Price:2.550|

Xenetic Biosciences Inc. (XBIO) is a biopharmaceutical company focused on immuno-oncology technologies, specifically advancing its Deoxyribonuclease (DNase) technology to treat difficult cancers. The company's DNase technology targets neutrophil extracellular traps (NETs) to improve existing cancer treatments, including immunotherapies. XBIO is developing this technology for …

Xenetic Biosciences Inc (XBIO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Xenetic Biosciences Inc (XBIO), identifying major individual and institutional holders. It provides a breakdown of shareholder types, including hedge funds, corporations, and individual investors, and lists institutional shareholding changes over several quarters. Key investors like Renaissance Technologies …

TradingKey

This article provides a detailed quarterly and annual income statement for Xenetic Biosciences Inc (XBIO) through FY2026Q1, emphasizing key financial metrics like total revenue, operating expenses, and net income. It also includes frequently asked questions about how to interpret these financial statements on the …

XBIO|Xenetic Biosciences Inc|Price:2.640|Chg%:-0.085

Xenetic Biosciences Inc. (XBIO) shows "relatively very healthy" fundamentals and high growth potential, though its valuation is considered "fairly valued" within the Biotechnology & Medical Research industry. The company, focused on immuno-oncology technologies, has seen steady revenue growth and holds significant institutional ownership. Despite …

Understanding the Setup: (XENE) and Scalable Risk

This article provides an in-depth analysis of Xenon Pharmaceuticals Inc. (XENE) using AI models to suggest trading strategies. It highlights a near-term neutral sentiment amidst mid and long-term strength, pointing out a significant short setup with a 34.6:1 risk-reward ratio. The analysis includes position, …

Xenon Pharmaceuticals (XENE) Q1 2025 earnings summary

Xenon Pharmaceuticals reported a Q1 2025 net loss of $65.0 million, an increase from the previous year, driven by higher R&D and G&A expenses. The company is nearing completion of patient recruitment for its pivotal XTOL-2/X-TOLE2 phase 3 epilepsy study, with top-line results expected …

Xenetic Biosciences (XBIO) Slides 1% as Shares Approach Key Support - Investment Factor

Xenon Pharmaceuticals advances with strong Phase 3 epilepsy data, eyeing NDA filing in 2026.

Xenon Pharmaceuticals is progressing with its lead drug candidate, azetukalner, for refractory focal onset seizures, showing strong effectiveness in Phase 3 trials and targeting an NDA filing in Q3 2026. The company is well-funded through 2029 for ongoing trials in other neurological conditions and …

Price to sales forward of Xenon Pharmaceuticals Inc. – TRADEGATE:XP0

This page provides financial data for Xenon Pharmaceuticals Inc. (TRADEGATE:XP0), specifically focusing on its forward price-to-sales ratio. The content indicates that the market was closed at the time of viewing, with no current trades.

XBIO Q2 2025 Earnings: EPS Beats Estimates Despite Revenue Absence and Stock Decline - Dividend Growth Analysis

Xenetic Biosciences (XBIO) Q2 2025 Earnings: EPS Surprises to the Upside with Narrower-Than-Expected Loss - Cost Structure Review

Xenetic Biosciences Inc. (XBIO) Stock Price | Live Quotes & Charts | NASDAQ

Should I buy Xenetic Biosciences (XBIO)

Xenetic Biosciences, Inc. Share Price Live Today – NASDAQ:XBIO Stock Price, Chart, News, History

Xenetic Biosciences Stock Price Forecast. Should You Buy XBIO?

XBIO: Xenetic Biosciences Inc Latest Stock Price, Analysis, News and Trading Ideas